Pulmonary infections caused by Methicillin-resistant Staphylococcus aureus represent a major therapeutic challenge, highlighting the need for efficient local antibiotic delivery. This study aimed to develop an extra-fine dry powder inhaler (DPI) formulation containing vancomycin (VAN) using nano spray drying. L-leucine (LEU) and D-mannitol (MAN) were applied as excipients to improve aerosolization. A Box–Behnken design was used to optimize the formulation parameters. Particle size analysis showed that the formulations had a mean diameter of approximately 2 μm, enabling effective lung targeting. The optimized formulation (VANSPD; VAN: MAN: LEU ratio 3: 2: 1) exhibited spherical morphology and acceptable flowability (Hausner ratio 1. 25; Carr index 19. 99). Structural analyses (DSC and FTIR) confirmed the absence of significant physicochemical interactions. The formulation demonstrated excellent in vitro aerodynamic performance with a mass median aerodynamic diameter of 2. 37 μm and a fine particle fraction of 79. 72%, exceeding that of commercially available formulations. In silico deposition modeling predicted efficient delivery to the bronchial and acinar regions of the lung, with approximately 56–60% deposition. In vitro cytotoxicity studies on alveolar cell lines confirmed good biocompatibility. Overall, the developed DPI formulation represents a promising platform for pulmonary VAN delivery. Further studies, including stability and in vivo efficacy investigations, are required to support its potential clinical application.
Party et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: